What is Anavex Life Sciences Financial Strength?
Anavex Life Sciences has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Anavex Life Sciences Corp shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Anavex Life Sciences has no long-term debt (1).
As of today, Anavex Life Sciences's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Anavex Life Sciences's Financial Strength
For the Biotechnology subindustry, Anavex Life Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Financial Strength falls into.
Anavex Life Sciences Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Anavex Life Sciences's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-11.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Anavex Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is
| Anavex Life Sciences had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Anavex Life Sciences's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Anavex Life Sciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
| Christopher U Missling |
director, officer: President, CEO, CFO, Treasurer, other: Secretary |
61 MOULTON ST, CAMBRIDGE MA 02138 |
| Athanasios Skarpelos |
10 percent owner |
14,RUE KLEBERG, GENEVA V8 CH-1201 |
| Jiong Ma |
director |
445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022 |
| Elliot Favus |
director |
51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091 |
| Donhauser Peter D.o. |
director |
REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600 |
| Sandra Boenisch |
officer: PFO & Treasurer |
51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
| Claus Vander Velden |
director |
PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937 |
| Steffen Thomas |
director |
FALLMERAYER STR. 19, MUNICH 2M 80796 |
| Bernd Metzner |
director |
51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
| George F Tidmarsh |
director, officer: Executive Director |
|
| John Robert Chisholm |
director |
16308 36A AVENUE, SURREY A1 V3S 0X5 |
| William Sean Lowry |
director |
1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9 |
| David L. Tousley |
director |
14610 PAWNEE LANE, LEAWOOD KS 66224 |
| Harvey Lalach |
director, officer: President CEO CFO |
4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1 |
| Alison E. Ayers |
director |
27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052 |
Anavex Life Sciences (Anavex Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your